HK1038497A1 - Methods for treating diabetes by inhibiting gdf-8 - Google Patents

Methods for treating diabetes by inhibiting gdf-8

Info

Publication number
HK1038497A1
HK1038497A1 HK01105702.7A HK01105702A HK1038497A1 HK 1038497 A1 HK1038497 A1 HK 1038497A1 HK 01105702 A HK01105702 A HK 01105702A HK 1038497 A1 HK1038497 A1 HK 1038497A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating diabetes
inhibiting gdf
gdf
inhibiting
Prior art date
Application number
HK01105702.7A
Other languages
English (en)
Inventor
Gideon Strassmann
Li-Fang Liang
Stavros Topouzis
Original Assignee
Metamorphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metamorphix Inc filed Critical Metamorphix Inc
Publication of HK1038497A1 publication Critical patent/HK1038497A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01105702.7A 1998-05-06 2001-08-14 Methods for treating diabetes by inhibiting gdf-8 HK1038497A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8449098P 1998-05-06 1998-05-06
PCT/US1999/010089 WO1999056768A1 (en) 1998-05-06 1999-05-06 Methods for treating diabetes by inhibiting gdf-8

Publications (1)

Publication Number Publication Date
HK1038497A1 true HK1038497A1 (en) 2002-03-22

Family

ID=22185291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105702.7A HK1038497A1 (en) 1998-05-06 2001-08-14 Methods for treating diabetes by inhibiting gdf-8

Country Status (9)

Country Link
US (6) US6368597B1 (ja)
EP (1) EP1075272B1 (ja)
JP (1) JP4544742B2 (ja)
AU (1) AU765214B2 (ja)
CA (1) CA2331410C (ja)
DE (1) DE69941116D1 (ja)
ES (1) ES2330062T3 (ja)
HK (1) HK1038497A1 (ja)
WO (1) WO1999056768A1 (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1075272B1 (en) * 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2470431A1 (en) * 2001-12-17 2003-06-26 Metabolex, Inc. Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
AU2003217612A1 (en) 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2513086A1 (en) * 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
DE60335915D1 (de) 2002-12-20 2011-03-10 Amgen Inc Myostatin hemmende bindungsstoffe
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
BRPI0418317A (pt) * 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
EP1778275A2 (en) * 2004-08-12 2007-05-02 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
WO2006073827A2 (en) * 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
CN103450359B (zh) 2005-08-19 2018-07-24 惠氏有限责任公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
BRPI0616923A2 (pt) * 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2632544C (en) * 2005-12-06 2014-09-23 Amgen Inc. Use of myostatin antagonist for treating the effects of hypogonadism
JP5058261B2 (ja) 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
JPWO2010134373A1 (ja) 2009-05-22 2012-11-08 株式会社エリナ メタボリックシンドロームの予防剤及び／又は治療剤
WO2011087946A1 (en) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
KR20140005864A (ko) 2010-08-16 2014-01-15 암젠 인코퍼레이티드 미오스타틴에 결합하는 항체, 조성물 및 방법
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
DK3564258T3 (da) 2012-09-13 2021-06-21 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CN104931327B (zh) * 2015-03-24 2018-10-19 重庆医科大学 微米级生物材料石蜡切片方法
EA201792298A1 (ru) 2015-04-15 2018-04-30 Регенерон Фармасьютикалз, Инк. Способы увеличения силы и функциональности с помощью ингибиторов gdf8
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
JP7411563B2 (ja) * 2018-10-12 2024-01-11 シーシーアイホールディングス株式会社 クラスｉのグルコーストランスポーター（ｇｌｕｔ）の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物
CN110408616B (zh) * 2019-07-09 2021-06-15 中南民族大学 GLUT4基因敲除的sgRNA、A549细胞系及其构建方法
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
EP1075272B1 (en) * 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US7056512B1 (en) * 1999-07-20 2006-06-06 Pharmexa A/S Method for down-regulating GDF-8 activity

Also Published As

Publication number Publication date
US20180134779A1 (en) 2018-05-17
US9150643B2 (en) 2015-10-06
WO1999056768A1 (en) 1999-11-11
DE69941116D1 (de) 2009-08-27
US20060121035A1 (en) 2006-06-08
JP2002513768A (ja) 2002-05-14
AU4183299A (en) 1999-11-23
AU765214B2 (en) 2003-09-11
US6368597B1 (en) 2002-04-09
US20160122424A1 (en) 2016-05-05
CA2331410A1 (en) 1999-11-11
US20020031517A1 (en) 2002-03-14
JP4544742B2 (ja) 2010-09-15
EP1075272B1 (en) 2009-07-15
ES2330062T3 (es) 2009-12-03
CA2331410C (en) 2009-07-14
EP1075272A1 (en) 2001-02-14
US20090035297A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HK1038497A1 (en) Methods for treating diabetes by inhibiting gdf-8
AU2001231104A1 (en) Methods for treating diabetes
IL122718A0 (en) Methods for treating diabetes
AU6200999A (en) Treatment for fabrics
GB9821218D0 (en) Treatment for fabrics
EP1215963A4 (en) METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES
AU3529399A (en) Well treatment for water restriction
ZA200202843B (en) Method for improving growth.
GB9821217D0 (en) Treatment for substrates
AU6263899A (en) Method for treating androgen-related conditions
IL142248A0 (en) Methods for treating sepsis
AU2777999A (en) Method for treating plants
GB0025583D0 (en) Technique for treating wells
IL137828A0 (en) Process for preparing protected 4-aminomethyl-pyrrolidin-3-one
HK1039449A1 (zh) 治療多發性硬化的方法
ZA994105B (en) Method for treating glaucoma.
AU2482400A (en) Advanced treatment for produced water
GB0009367D0 (en) Method for protecting bytecode
PL343313A1 (en) Methods for inhibiting mrp1
HK1033551A1 (en) Method for treating copd.
IL138391A0 (en) Methods for inhibiting mrp1
EP1199347A4 (en) METHOD FOR TREATING RAW OIL
PL343320A1 (en) Methods for inhibiting mrp1
HUP0102016A3 (en) Method for copperplating substrates
AU6824400A (en) Process for treating fabrics

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190505